Register a trial

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05480020




Registration number
NCT05480020
Ethics application status
Date submitted
27/07/2022
Date registered
29/07/2022

Titles & IDs
Public title
Probiotic Toothpaste for Microbial Colonization
Scientific title
Colonisation Efficacy of Streptococcus Salivarius M18 Toothpaste
Secondary ID [1] 0 0
BLTCT2022/5
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Microbial Colonization 0 0
Condition category
Condition code
Infection 0 0 0 0
Studies of infection and infectious agents
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Sexually transmitted infections

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Streptococcus salivarius M18 toothpaste
Other interventions - Streptococcus salivarius M18 toothpaste
Other interventions - Streptococcus salivarius M18 toothpaste

Active comparator: Streptococcus salivarius M18 toothpaste dose 1 - Streptococcus salivarius M18 toothpaste containing 1 million cfu/g

Active comparator: Streptococcus salivarius M18 toothpaste dose 2 - Streptococcus salivarius M18 toothpaste containing 10 million cfu/g

Active comparator: Streptococcus salivarius M18 toothpaste dose 3 - Streptococcus salivarius M18 toothpaste containing 100 million cfu/g


Other interventions: Streptococcus salivarius M18 toothpaste
Probiotics Streptococcus salivarius M18 toothpaste 1 million cfu/g

In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity.

Other interventions: Streptococcus salivarius M18 toothpaste
Probiotics Streptococcus salivarius M18 toothpaste 10 million cfu/g

In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity.

Other interventions: Streptococcus salivarius M18 toothpaste
Probiotics Streptococcus salivarius M18 toothpaste 100 million cfu/g

In this study, a toothpaste formulation containing S. salivarius M18 will be evaluated for its potential for delivering the probiotic to the oral cavity.
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change in Microbial colonization from baseline (Day 0) to 1 hour
Timepoint [1] 0 0
1 hour post intervention
Primary outcome [2] 0 0
Change in Microbial colonization from baseline (Day 0) to 8 hours
Timepoint [2] 0 0
8 hours post intervention
Primary outcome [3] 0 0
Change in Microbial colonization from baseline (Day 0) to 24 hours
Timepoint [3] 0 0
24 hours post intervention
Primary outcome [4] 0 0
Change in Microbial colonization from baseline (Day 0) to 24 hours post last dose
Timepoint [4] 0 0
24 hours after last dose following 7 days of daily brushing with probiotic toothpaste.

Eligibility
Key inclusion criteria
* In general good health
* Practise good oral hygiene
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. Have a history of autoimmune disease or are immunocompromised.
2. Are on concurrent antibiotic therapy or regular antibiotic use within last 1 week
3. History of allergy (e.g. dairy).

Study design
Purpose of the study
Other
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


Intervention assignment
Parallel
Other design features
Phase
NA
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
UNKNOWN
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
1/08/2022
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/10/2022
Actual
Sample size
Target
30
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0
Otago

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
John Hale
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
John R Tagg, PhD
Address 0 0
Blis Technologies
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
John D Hale, PhD
Address 0 0
Country 0 0
Phone 0 0
+6434740988
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT05480020